MA45684A - Protéine d'apport du cerveau - Google Patents

Protéine d'apport du cerveau

Info

Publication number
MA45684A
MA45684A MA045684A MA45684A MA45684A MA 45684 A MA45684 A MA 45684A MA 045684 A MA045684 A MA 045684A MA 45684 A MA45684 A MA 45684A MA 45684 A MA45684 A MA 45684A
Authority
MA
Morocco
Prior art keywords
supply protein
brain supply
brain
protein
supply
Prior art date
Application number
MA045684A
Other languages
English (en)
Inventor
Greta Hultqvist
Lars Lannfelt
Dag Sehlin
Stina Syvänen
Original Assignee
Bioarctic Neuroscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Neuroscience Ab filed Critical Bioarctic Neuroscience Ab
Publication of MA45684A publication Critical patent/MA45684A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70582CD71

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA045684A 2016-07-14 2017-07-13 Protéine d'apport du cerveau MA45684A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1651065 2016-07-14

Publications (1)

Publication Number Publication Date
MA45684A true MA45684A (fr) 2019-05-22

Family

ID=59593007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045684A MA45684A (fr) 2016-07-14 2017-07-13 Protéine d'apport du cerveau

Country Status (15)

Country Link
US (1) US11498974B2 (fr)
EP (1) EP3484918A1 (fr)
JP (2) JP2019529345A (fr)
KR (1) KR20190039696A (fr)
CN (1) CN109476728A (fr)
AU (1) AU2017297804A1 (fr)
BR (1) BR112019000098A2 (fr)
CA (1) CA3028035A1 (fr)
IL (1) IL263773A (fr)
MA (1) MA45684A (fr)
MX (1) MX2019000529A (fr)
PH (1) PH12018502451A1 (fr)
RU (1) RU2019102746A (fr)
SG (2) SG11201810801QA (fr)
WO (1) WO2018011353A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506055A (zh) 2017-02-17 2019-11-26 戴纳立制药公司 工程改造的转铁蛋白受体结合多肽
CA3051839A1 (fr) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Anticorps anti-alpha-synucleine et leurs utilisations
CA3118692A1 (fr) * 2018-11-06 2020-05-14 Alsatech, Inc. Therapie genique de maladies neurodegeneratives a base de cellules
CN121754667A (zh) * 2020-04-08 2026-03-31 阿里亚达治疗公司 用于血脑屏障递送的组合物和方法
CA3220572A1 (fr) 2021-06-11 2022-12-15 Bioarctic Ab Molecule de liaison bispecifique
WO2023128702A1 (fr) * 2021-12-31 2023-07-06 주식회사 아임뉴런 Protéine de fusion perméable à la barrière hémato-encéphalique et ses utilisations
US20250304709A1 (en) * 2022-05-05 2025-10-02 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
WO2024080843A1 (fr) * 2022-10-14 2024-04-18 주식회사 아임뉴런 Protéine de fusion perméable à la barrière hémato-encéphalique et son utilisation
EP4631975A1 (fr) * 2022-12-08 2025-10-15 Adel Inc. Protéine de fusion comprenant un anticorps anti-tau et un peptide et utilisation associée
KR20250162888A (ko) 2023-03-24 2025-11-19 바이오악틱 에이비 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 이중특이적 항체
US20250000992A1 (en) * 2023-06-21 2025-01-02 Eli Lilly And Company Compounds for the delivery of granulin across the blood brain barrier
CN121773136A (zh) * 2023-07-04 2026-03-31 北京星奇原生物科技有限公司 抗-TfR1抗体及其用途
WO2025262228A1 (fr) 2024-06-20 2025-12-26 Bioarctic Ab Molécule de liaison bispécifique
WO2025262225A1 (fr) 2024-06-20 2025-12-26 Bioarctic Ab Molécule de liaison stabilisée
WO2026068513A1 (fr) 2024-09-24 2026-04-02 Bioarctic Ab Molécule de liaison bispécifique
WO2026068532A1 (fr) 2024-09-24 2026-04-02 Bioarctic Ab Molécule de liaison bispécifique
WO2026068519A1 (fr) 2024-09-24 2026-04-02 Bioarctic Ab Molécule de liaison sensible au ph

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (fr) 2000-07-07 2011-06-28 Jan Naslund Prevention et traitement de la maladie d'alzheimer
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
PT2282758T (pt) 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
EP2769711A1 (fr) 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Procédés et compositions favorisant l'administration de macromolécules
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
KR101849738B1 (ko) 2010-06-17 2018-04-17 트렐리스 바이오싸이언스 인코포레이티드 수동 인플루엔자 면역에 유용한 항체
CA2818173C (fr) 2010-11-30 2022-05-03 Genentech, Inc. Anticorps anti-recepteur de la barriere hemato-encephalique a faible affinite et leurs utilisations
HUE045144T2 (hu) * 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
AU2014332442B2 (en) * 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
CA2944402A1 (fr) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Navettes de la barriere hemato-encephalique contenant des anticorps reconnaissant l'alpha-synucleine
WO2016005466A2 (fr) * 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab Anticorps se liant aux protofibrilles ass améliorés

Also Published As

Publication number Publication date
JP2019529345A (ja) 2019-10-17
SG10201912842VA (en) 2020-02-27
MX2019000529A (es) 2020-01-15
CA3028035A1 (fr) 2018-01-18
RU2019102746A3 (fr) 2020-11-30
KR20190039696A (ko) 2019-04-15
IL263773A (en) 2019-02-28
AU2017297804A1 (en) 2019-01-24
BR112019000098A2 (pt) 2019-04-09
US11498974B2 (en) 2022-11-15
CN109476728A (zh) 2019-03-15
JP7589194B2 (ja) 2024-11-25
JP2022130646A (ja) 2022-09-06
EP3484918A1 (fr) 2019-05-22
US20190225699A1 (en) 2019-07-25
SG11201810801QA (en) 2019-01-30
PH12018502451A1 (en) 2019-09-30
WO2018011353A1 (fr) 2018-01-18
RU2019102746A (ru) 2020-08-14

Similar Documents

Publication Publication Date Title
MA45684A (fr) Protéine d'apport du cerveau
EP3430731A4 (fr) Architecture d'iugw
EP3463146A4 (fr) Ensembles chirurgicaux robotiques
EP3547968A4 (fr) Prothèse obtenu par génie tissulaire
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
KR20180085041A (ko) 칫솔
EP3518708A4 (fr) Structure d'assise souple
IL262776A (en) Humanized anti-il-1r3 antibodies
EP3437540A4 (fr) Support d'endoscope
HRP20190412T1 (hr) Konstrukti proteina uspa2 i njihova upotreba
DK3145946T3 (da) Bakteriebaseret proteintilførsel
MA50174A (fr) Formules de protéines de fusion vegfr-fc
HUE064240T2 (hu) Fehérjetisztítás
EP3487471A4 (fr) Tétine artificielle de protection contre les morsures
IL260347A (en) Therapeutic anti-cd9 antibody
DK3737402T5 (da) Modificeret protein
MA43873A (fr) Dspositif d'injection
EP3525479A4 (fr) Casque d'écoute
EP3583844A4 (fr) Système d'aquaculture
EP3512771A4 (fr) Siège d'aéronef
EP3431808A4 (fr) Butée d'arrêt
EP3445974A4 (fr) Réchauffeur d'air
EP3444345A4 (fr) Dérivé d'arnmicro-143
ZA201902689B (en) Therapeutic protein
EP3343013A4 (fr) Collecteur d'admission